Skip to main content
. 2025 Nov 10;32(11):630. doi: 10.3390/curroncol32110630
BRAFi BRAF V600 inhibitor
MEKi MEK inhibitor
ATB Antibiotic
ICI Immune checkpoint inhibitor
ORR Overall response rate
PFS Progression-free survival
mPFS Median progression-free survival
OS Overall survival
mOS Median overall survival
HR Hazard ratio
CI Confidence interval
BMT Bone marrow transplantation
CAR-T Chimeric antigen receptor T-cell therapy
NSCLC Non–small cell lung cancer
RCC Renal cell carcinoma